Vidarbha News

Focal Segmental Glomerulosclerosis Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

 Breaking News
  • No posts were found

Focal Segmental Glomerulosclerosis Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

September 15
20:18 2023
Focal Segmental Glomerulosclerosis Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

DelveInsight’s, “Focal Segmental Glomerulosclerosis Pipeline Insight 2023,” report provides comprehensive insights about 15+ companies and 18+ pipeline drugs in the Focal Segmental Glomerulosclerosis pipeline landscape. It covers the Focal Segmental Glomerulosclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Focal Segmental Glomerulosclerosis Pipeline Report

  • DelveInsight’s Focal Segmental Glomerulosclerosis pipeline report depicts a robust space with 15+ active players working to develop 18+ pipeline therapies for Focal Segmental Glomerulosclerosis treatment.
  • The leading companies working in the Focal Segmental Glomerulosclerosis Market include Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4,  and others.
  • Promising Focal Segmental Glomerulosclerosis Pipeline Therapies in the various stages of development include Propagermanium, Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), CXA-10, RE-021 (Sparsentan), Irbesartan, Fresolimumab, GC1008, VX-147, and others.
  • In May 2023, Travere Therapeutics Inc. announced a study of Phase 2 Clinical Trials for RE-021 (Sparsentan) and Irbesartan. This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS).
  • On July 2023, Vertex Pharmaceuticals Incorporated announced a study of Phase 2 Clinical Trials for VX-147. This study will evaluate the efficacy, safety, and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

 

Request a sample and discover the recent advances in Focal Segmental Glomerulosclerosis Treatment Drugs @ Focal Segmental Glomerulosclerosis Pipeline Report

 

The Focal Segmental Glomerulosclerosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Focal Segmental Glomerulosclerosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Focal Segmental Glomerulosclerosis clinical trial landscape.

 

Focal Segmental Glomerulosclerosis Overview

Focal Segmental Glomerulosclerosis (FSGS) is a major cause of idiopathic steroid-resistant nephrotic syndrome (SRNS) and end-stage kidney disease (ESKD). The pathogenesis of focal segmental glomerular sclerosis involves a complex interplay of several cell types, including podocytes, endothelial cells, and the basement membrane.

 

Find out more about Focal Segmental Glomerulosclerosis Treatment Drugs @ Drugs for Focal Segmental Glomerulosclerosis Treatment

 

Focal Segmental Glomerulosclerosis Emerging Drugs Profile

  • DMX-200: Dimerix Bioscience
  • Sparsentan: Travere Therapeutics
  • Dazodalibep: Horizon Therapeutics

 

Focal Segmental Glomerulosclerosis Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the therapies for Focal Segmental Glomerulosclerosis. The Focal Segmental Glomerulosclerosis companies which have their Focal Segmental Glomerulosclerosis drug candidates in the most advanced stage, i.e. phase III include, Dimerix Bioscience.

 

Learn more about the emerging Focal Segmental Glomerulosclerosis Pipeline Therapies @ Focal Segmental Glomerulosclerosis Clinical Trials Assessment

 

Scope of the Focal Segmental Glomerulosclerosis Pipeline Report

  • Coverage- Global
  • Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Focal Segmental Glomerulosclerosis Companies- Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4, and others.
  • Focal Segmental Glomerulosclerosis Pipeline Therapies- Propagermanium, Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), CXA-10, RE-021 (Sparsentan), Irbesartan, Fresolimumab, GC1008, VX-147, and others.

 

Dive deep into rich insights for new drugs for Focal Segmental Glomerulosclerosis Treatment, Visit @ Focal Segmental Glomerulosclerosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Focal Segmental Glomerulosclerosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Focal Segmental Glomerulosclerosis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. DMX-200: Dimerix Bioscience
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Dazodalibep: Horizon Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Focal Segmental Glomerulosclerosis- Unmet Needs
  21. Focal Segmental Glomerulosclerosis- Market Drivers and Barriers
  22. Appendix

 

For further information on the Focal Segmental Glomerulosclerosis Pipeline therapeutics, reach out to Focal Segmental Glomerulosclerosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting

Categories